Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00841477
First received: February 10, 2009
Last updated: March 12, 2009
Last verified: February 2009

February 10, 2009
March 12, 2009
January 2004
June 2007   (final data collection date for primary outcome measure)
compliance (adherence) for 3 doses hepatitis vaccination [ Time Frame: Jan, 2004 - June 2008 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00841477 on ClinicalTrials.gov Archive Site
  • incidence of HIV and HCV infection and change of risk behaviors [ Time Frame: Jan, 2004- June 2009 ] [ Designated as safety issue: No ]
  • immunological response [ Time Frame: Feb 2004 - June 2008 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

The goal of the proposed study is to use the HBV vaccine as a model for a future HIV vaccine trial, examining the efficacy of community-based outreach intervention as well as an accelerated vaccine schedule as a method for increasing acceptance/adherence with HBV vaccination protocols among not-in-treatment drug users. This study will also examine the effect of HBV vaccination coupled with community-based outreach intervention on reducing the incidence of HIV, HBV and HCV infections and the frequency of needle use and sexual risk behaviors related to these viral transmissions. A secondary purpose will be to assess the antibody response after HBV vaccination as a measurement of immunological response in drug users.

This project will evaluate an HBV vaccination program as a model for future HIV vaccine efficacy trials in a community-based study of drug users. Two components will be analyzed in an effort to increase vaccine acceptance/adherence - behavioral intervention & an accelerated vaccine schedule. The study also will examine the effect of these variables on risk behaviors and incidence of HIV, HBV, & HCV infections. To accomplish these objectives, we propose a randomized behavioral intervention field trial. We will enroll 1600 current cocaine or heroin users negative for HBV & HIV markers from two closely matched, low-income, high drug endemic communities in Houston. All participants will be offered HBV vaccination and follow-up viral testing. One community will be randomly assigned to receive an outreach behavioral intervention designed to increase vaccine awareness and vaccine compliance. The other community will receive standard care. Participants electing to be vaccinated will be randomized to either a 0,1,6 month or a 0,1,2, month vaccine schedule. Groups will be followed for two years to determine rates of HBV vaccine acceptance/adherence to the 3-dose protocol. We also will measure any changes in risk behaviors & incidence of HIV/HBV/HCV infections as well as HBV vaccine immune response, if vaccinated. Drug users are the largest group of newly diagnosed HIV cases and so creating a model for an HIV vaccine's acceptance and adherence in this population is an important public health goal. This study will serve as a model for future HIV vaccine trials and will provide information on the effectiveness of outreach programs for increasing immunization among drug users. Unless an effective model based upon empirical experience is developed, any attempt to implement a HIV vaccination program among drug users is likely to be frustrated. If HBV vaccination coupled with outreach intervention can reduce risk behaviors and decrease the incidence of HIV/HCV infection, then this study will have a tremendous impact on the current HBV/HIV/HCV prevention strategy.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
  • Using Cocaine or Heroin in the Last 7 Days,
  • Age Over 18 Years Old,
  • Competent to Sign Informed Consent for HIV/HBV/HCV Testing,
  • HIV/HBV Negatives Will be Randomized for HB Vaccine Study
  • HIV Infections
  • Biological: hepatitis B vaccine schedule
    hepatitis B vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated hepatitis B vaccine schedule (0,1,2month) vs standard hepatitis B vaccine
    Other Name: vaccine dose schedules
  • Behavioral: HBV Vaccination Self-Efficacy Intervention
    HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake; Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
    Other Name: enhanced behavioral intervention
  • No Intervention: A1
    standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
  • Active Comparator: A2
    standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
    Intervention: Biological: hepatitis B vaccine schedule
  • Active Comparator: B1
    enhanced behavioral intervention, standard vaccine schedule
    Intervention: Behavioral: HBV Vaccination Self-Efficacy Intervention
  • Active Comparator: B2
    enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
    Interventions:
    • Biological: hepatitis B vaccine schedule
    • Behavioral: HBV Vaccination Self-Efficacy Intervention
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1260
June 2009
June 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • using cocaine/heroin in last 7 days, age over 18 years old from two matched in population size, income and demographic communities, known with high rate of drug using and STD; competent to consent for urine drug screening and viral markers (anti-HIV, HBsAg/anti-HBs, anti-HCV) testing; those negative for HIV/HBV will be contacted for HB vaccination study.

Exclusion Criteria:

  • age under 18 or not from the target communities, negative for urine drug test.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00841477
DESPR DA017505, R01 DA017505-05
Yes
Lu-Yu Hwang. M.D./Professor of Epidemiology, University of Texas Health Scienter-Houston, School of Public Health
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Lu-Yu Hwang, MD University of Texas-HSC at Houston
National Institute on Drug Abuse (NIDA)
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP